Citadel Advisors
PHAR

Citadel Advisors’s Pharming Group PHAR Stock Holding History

Citadel Advisors’s Portfolio PHAR Stock Details PHAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
11,972
+1,783
+17% +$25.8K ﹤0.01% 12275
2026
Q1 		$170K Sell
10,189
-7,501
-42% -$127K ﹤0.01% 11577
2025
Q4 		$313K Buy
+17,690
New +$278K ﹤0.01% 10043

Other funds holding PHAR

MACM
MAC Alpha Capital Management Tampa, Florida $216M AUM
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
SGFG
Silver Grove Financial Group Orchard Park, New York $185M AUM 28.01% 1-Year Est. Return
NSG
Nalls Sherbakoff Group Knoxville, Tennessee $141M AUM 25.05% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citadel Advisors's PHAR Position: Q2 2026 in Review

Citadel Advisors increased its Pharming Group (PHAR) stake by 17% in Q2 2026, buying an estimated $25.8K and bringing the position to 11,972 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #12275.

Citadel Advisors first reported a position in PHAR in Q4 2025 and has held it in 3 quarters since. The position peaked at $313K in Q4 2025. 17 funds tracked by Wall St. Rank hold PHAR as of Q2 2026.

  • Citadel Advisors held 11,972 shares of Pharming Group worth $162K as of Q2 2026.
  • Citadel Advisors bought 1,783 Pharming Group shares in Q2 2026, an estimated $25.8K.
  • Pharming Group made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12275 holding.
  • Citadel Advisors first reported a position in Pharming Group in Q4 2025 and has held it in 3 quarters since.
  • Citadel Advisors's Pharming Group position peaked at $313K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pharming Group as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.